CCIA
NTLA icon

Campbell & Co Investment Adviser’s Intellia Therapeutics NTLA Stock Holding History

Campbell & Co Investment Adviser’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-55,319
Closed -$497K – 1309
2025
Q4 		$497K Buy
+55,319
New +$762K 0.02% 829
2025
Q2 		– Sell
-28,302
Closed -$201K – 1359
2025
Q1 		$201K Buy
+28,302
New +$286K 0.02% 942
2023
Q1 		– Sell
-14,768
Closed -$515K – 964
2022
Q4 		$515K Buy
+14,768
New +$702K 0.12% 297
2022
Q3 		– Sell
-6,822
Closed -$353K – 855
2022
Q2 		$353K Buy
6,822
+2,959
+77% +$150K 0.1% 400
2022
Q1 		$281K Buy
+3,863
New +$327K 0.08% 502

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $121B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return